参考文献/References:
[1] 翁方中,胡朝梁,严骏,等.Relaxin-3通过抑制HMGB1介导的NLRP3炎性小体活化抑制AngⅡ诱导的心肌成纤维细胞转分化[J].川北医学院学报,2021,36(8):953-958.
WENG F Z,HU C L,YAN J,et al.Relaxin-3 inhibits Ang Ⅱ-induced cardiac fibroblast transdifferentiation by inhibiting HMGB1-mediated activation of NLRP3 inflammasome[J].J North Sichuan Med Coll,2021,36(8):953-958.
[2] 罗立,熊沿,聂晓红.慢性阻塞性肺疾病急性加重患者血NLR、CRP、EOS水平与病情严重程度的相关性[J].川北医学院学报,2021,36(8):1006-1009.
LUO L,XIONG Y,NIE X H.Relationship between blood NLR,CRP,EOS levels and disease severity in patients with acute exacerbation of chronic obstructive pulmonary disease[J].J North Sichuan Med Coll,2021,36(8):1006-1009.
[3] 侯梦瑶,邵明琨,罗丹丹,等.不同Sap酶活性的白假丝酵母菌对阴道上皮细胞表达NLRP3炎性小体的影响[J].安徽医科大学学报,2021,56(10):1555-1560.
HOU M Y,SHAO M K,LUO D D,et al.Effect of Candida albicans with different Sap enzyme activities on NLRP3 inflammasomeexpression in vaginal epithelial cells[J].J Anhui Med Univ,2021,56 (10):1555-1560.
[4] JIN X,FU W,ZHOU J,et al.Oxymatrine attenuates oxidized low-density lipoprotein induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway[J].Int J Mol Med,2021,48(4):261-265.
[5] 梁海梅,欧宗兴,齐见旭,等.慢性阻塞性肺疾病急性加重期患者血清IL-34水平的变化及临床意义分析[J].临床肺科杂志,2021,26(9):1431-1433.
LIANG H M,OU Z X,QI J X,et al.Changes and clinical significance of serum IL-34 levels in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Clin J Pulmon Med,2021,26 (9):1431-1433.
[6] 刘威,龙政,由金玲,等.2019年中国居民慢性阻塞性肺疾病死亡地点及影响因素分析[J].中国慢性病预防与控制,2021,29(8):561-566.
LIU W,LONG Z,YOU J L,et al.Analysis of death places and influencing factors of chronic obstructive pulmonary disease among Chinese residents in 2019[J].Chin J Prev Control Chron Dis,2021,29 (8):561-566.
[7] CHUNSU Z,BO Z,JIAHAO Q,et al.Gout-associated monosodium urate crystal-induced necrosis is independent of NLRP3 activity but can be suppressed by combined inhibitors for multiple signaling pathways[J].Acta Pharmacol Sin,2021,56(19):11515-11519.
[8] QIN L,LIQIANG W,JING S,et al.Black carbon induces complement activation via NLRP3 inflammasome in human corneal epithelial cells[J].Curr Eye Res,2021,59(46):16874-16878.
[9] MANGAN M,OLHAVA E J,ROUSH W R,et al.Targeting the NLRP3 inflammasome in inflammatory diseases[J].Nat Rev Drug Discov,2018,17(8):588-606.
[10] ZHEN Y,ZHANG H.NLRP3 inflammasome and inflammatory bowel disease[J].Front Immunol,2019,10(26):276.
[11] LAREAU S C,FAHY B,MEEK P,et al.Chronic obstructive pulmonary disease (COPD)[J].Am J Respir Crit Care Med,2019,199(1):1-2.
[12] CASSADY S J,REED R M.Pulmonary hypertension in COPD:a case study and review of the literature[J].Medicina (Kaunas),2019,55(8):4625-4629.
[13] POLVERINO F,SAM A,GUERRA S.COPD:to be or not to be,that is the question[J].Am J Med,2019,132(11):1271-1278.
[14] 陈凌,茅松,朱若尘,等.NLRP3抑制剂MCC950对中性粒细胞性哮喘气道炎症的影响及其作用机制[J].中国生物制品学杂志,2022,35(7):829-835.
CHEN L,MAO S,ZHU R C,et al.Effect of NLRP3 inhibitor MCC950 on airway inflammation in neutrophilic asthma and its mechanism[J].Chin J Biol,2022,35(7):829-835.
[15] AGUST A,VOGELMEIER C,FANER R.COPD 2020:changes and challenges[J].Am J Physiol Lung Cell Mol Physiol,2020,319(5):879-883.
[16] KELLEY N,JELTEMA D,DUAN Y,et al.The NLRP3 inflammasome:an overview of mechanisms of activation and regulation[J].Int J Mol Sci,2019,20(13):6151-6158.
[17] ZHAO C,ZHAO W.NLRP3 inflammasome:a key player in antiviral responses[J].Front Immunol,2020,11(62):211.
[18] HOOFTMAN A,ANGIARI S,HESTER S,et al.The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation[J].Cell Metab,2020,32(3):468-478.
[19] SEOANE P I,LEE B,HOYLE C,et al.The NLRP3-inflammasome as a sensor of organelle dysfunction[J].J Cell Biol,2020,219(12):5618-5622.
[20] 杨美琪,刘维新,来爽,等.核苷酸结合寡聚化结构域样受体蛋白1、3、6与炎症性肠病的关系[J].中国医科大学学报,2019,48(5):457-460.
YANG M Q,LIU W X,LAI S,et al.Relationship between nucleotide-binding oligomerization domain-like receptor proteins 1,3,and 6 and inflammatory bowel disease[J].J China Med Univ,2019,48(5):457-460.
[21] 刘萍,娄可,文隆,等.氧化应激介导NLRP3炎性反应小体对慢性阻塞性肺疾病的影响研究[J].首都医科大学学报,2020,41(1):131-136.
LIU P,LOU K,WEN L,et al.Oxidative stress mediates the effect of NLRP3 inflammasome on chronic obstructive pulmonary disease[J].J Capital Med Univ,2020,41(1):131-136.
[22] 赵开顺,楚亚萍,余艳芳,等.慢性阻塞性肺疾病急性发作患者血清CG、NT-proBNP、HIF-1α和NLRP 3蛋白表达的意义[J].四川医学,2019,40(1):79-82.
ZHAO K S,CHU Y P,YU Y F,et al.The significance of serum CG,NT-proBNP,HIF-1α and NLRP3 protein expression in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Sichuan Med J,2019,40(1):79-82.
相似文献/References:
[1]史册.慢性阻塞性肺疾病急性发作期的营养支持治疗[J].新乡医学院学报,2001,18(06):444.
[2]袁晓梅,孙 云,袁宇.慢性阻塞性肺疾病肺心病患者血浆内皮素测定的临床价值[J].新乡医学院学报,2002,19(04):273.
[3]郭志强.慢性阻塞性肺疾病60例院内获得性真菌感染与耐药性分析 [J].新乡医学院学报,2006,23(02):000.
[4]程思远.慢性阻塞性肺疾病继发真菌感染65例病原菌分布及耐药性分析[J].新乡医学院学报,2009,26(01):073.
[5]杨华,周志才,奚峰,等.无创正压通气治疗慢性阻塞性肺疾病急性加重期伴Ⅱ型呼吸衰竭[J].新乡医学院学报,2011,28(02):216.
[6]殷波,惠复新,赵寅滢,等.慢性阻塞性肺疾病急性加重期三重酸碱失衡与急性生理学和慢性健康状况评分Ⅲ评分及预后的关系 [J].新乡医学院学报,2011,28(03):346.
[7]刘金花,徐吟亚,付波.低分子肝素钙对慢性阻塞性肺疾病急性加重期患者血栓前状态的影响[J].新乡医学院学报,2012,29(09):680.
[8]王 沁,郭建辉,梁 栋,等.健脾益肺口服液对慢性阻塞性肺疾病“肺脾气虚证”大鼠动脉血气的影响[J].新乡医学院学报,2014,31(11):896.[doi:10.7683/xxyxyxb.2014.11.00]
[9]朱木林1,袁云华1,邓 巍2,等.慢性阻塞性肺疾病合并外周骨骼肌功能障碍患者炎性因子和代谢水平及线粒体功能的变化[J].新乡医学院学报,2015,32(05):412.
[10]李 航,郭伟丽,安 珍,等.PM2.5对慢性阻塞性肺疾病影响研究进展[J].新乡医学院学报,2016,33(3):234.[doi:10.7683/xxyxyxb.2016.03.020]
LI Hang,GUO Weili,AN Zhen,et al.Research progress on the effect of PM2.5 on chronic obstructive pulmonary disease[J].Journal of Xinxiang Medical University,2016,33(9):234.[doi:10.7683/xxyxyxb.2016.03.020]